Search Results

1-7 of 7 results for askedby:"Patsy Calton"

Show detailed: On Off

Results: 10 20 50 100

Sort by: Newest first Oldest first

To ask the Secretary of State for Health, what statistics his Department collates on the incidence of blood-borne diseases in recipients of blood products; and if he will make a statement. - ot available centrally.

Asked by

Patsy Calton (Liberal Democrat)

Answering body

Department of Health

Type

Written questions

Status

Answered

Date

12 January 2004

Reference

145448; 416 c594W;416 c592W

House

House of Commons

Dept of Health

To ask the Secretary of State for Health, if he will make a statement on the safety of the drug Seroxat. - Includes ref to 406 c42-3WS, 10 June 2003.

Asked by

Patsy Calton (Liberal Democrat)

Answering body

Department of Health

Type

Written questions

Status

Answered

Date

2 July 2003

Reference

115789; 408 c354W;408 c348W

House

House of Commons

Dept of Health

To ask the Secretary of State for Health, what recent assessment has been made of the risks from Seroxat to adults suffering from depression. - Including ref to 20 June 2003, 407 c488-9W.

Asked by

Patsy Calton (Liberal Democrat)

Answering body

Department of Health

Type

Written questions

Status

Answered

Date

1 July 2003

Reference

121263; 408 c234W

House

House of Commons

Dept for Culture Media and Sport

To ask the Secretary of State for Culture, Media and Sport, whether events covered by a temporary event notice, as set out in the Licensing Bill, will be covered by fire and safety legislation.

Asked by

Patsy Calton (Liberal Democrat)

Answering body

Department for Culture, Media and Sport

Type

Written questions

Status

Answered

Date

25 June 2003

Reference

119867; 407 c818W;407 c822W

House

House of Commons

Dept of Health

To ask the Secretary of State for Health, what plans he has to expedite the review of (a) Seroxat and (b) other selective serotonin reuptake inhibitors; what plans he has to improve the warnings given to (a) prescribers and (b) the public about the (i) side-effects and (ii) withdrawal effects...

Asked by

Patsy Calton (Liberal Democrat)

Answering body

Department of Health

Type

Written questions

Status

Answered

Tabled on

12 June 2003

For answer on

20 June 2003

Answered on

20 June 2003

Mrs. Calton: To ask the Secretary of State for Health (1) what plans he has to expedite the review of (a) Seroxat and (b) other selective serotonin reuptake inhibitors; [119777] (2) what plans he has to improve the warnings given to (a) prescribers and (b) the public about the (i) side-effects and (ii) withdrawal effects of (A) Seroxat and (B) other selective serotonin reuptake inhibitors; [119778] (3) what plans he has to improve the effectiveness of the Yellow Card scheme for reporting adverse side- effects of drugs; [119779] (4) if he will withdraw Seroxat from use for new prescribing pending a review of its and other SSRI anti- depressants' safety. [119780] Dr. Ladyman: A new expert group of the Committee on Safety of Medicines (CSM) has been convened to further review the safety of selective serotonin re-uptake inhibitors (SSRIs) and to ensure the advice in the product information for both patients and prescribers is optimal for the safe use of these products. This group has been asked to examine what implications, if any, the CSM's recent advice on the use of Seroxat in children have for the use of Seroxat in adults and for other SSRIs. The timetable for the group's programme of work has been planned with a view to the availability of advice as promptly as possible, commensurate with a full and detailed consideration of the evidence including the experiences of patients. As part of its initial considerations, the group has advised on strengthened advice on side effects and withdrawal reactions for inclusion in the patient information leaflet on Seroxat. Product information for other SSRIs will also be considered. The advice of the CSM, most recently in 2001, is that the benefits of Seroxat, when used in adults for licensed indications, outweigh the risks. Regulatory authorities world-wide have also taken a similar position. Depression and anxiety disorders are serious conditions that can cause severe suffering and are associated with an increased risk of suicide. The availability of effective treatments is critically important. In the absence of evidence indicating that the risks of using Seroxat in adults outweigh the benefits, it would be difficult to justify withdrawing the medicine from use. The Yellow Card Scheme is recognised to be one of the best in the world in terms of the level of reporting, has a proven track record of identifying new drug safety hazards and enables the monitoring of all medicines, including Seroxat, in clinical use. The effectiveness of the Scheme is under continuous review by the Medicines and Healthcare products Regulatory Agency and the CSM. From April 2003, the first phase of patient reporting of suspected adverse drug reactions via NHS Direct was introduced. When fully rolled out in England and Wales, this will enable the first hand experiences of patients to be utilised in the identification and assessment of drug safety issues. Other measures to further strengthen the Yellow Card Scheme include a new regional monitoring centre, established in Scotland last year and the inclusion of education on yellow card reporting in the training of nurse prescribers.

Date

20 June 2003

Reference

407 c488-9W;407 c489-90W; 119777;119778;119779;119780

House

House of Commons

Office of the Deputy Prime Minister

To ask the Deputy Prime Minister, what plans he has (a) to license houses in multiple occupation and (b) to introduce a new housing, health and safety system.

Asked by

Patsy Calton (Liberal Democrat)

Answering body

Office of the Deputy Prime Minister

Type

Written questions

Status

Answered

Date

7 January 2003

Reference

88548; 397 c114W

House

House of Commons

Dept for Education and Skills

To ask the Secretary of State for Education and Skills, what steps are being taken to ensure that schools provide sufficient curriculum time for school swimming in order to meet National Curriculum targets; when she will provide further details of the increased training of PE teachers in swimming and water...

Asked by

Patsy Calton (Liberal Democrat)

Answering body

Department for Education and Skills

Type

Written questions

Status

Answered

Date

6 November 2002

Reference

392 c395-6W;392 c415-6W; 79276;79277;79278;79182

House

House of Commons

Librarians' tools

Type

House

Session

Year

Department

Member

Primary member

Answering member

Legislative stage

Legislation

Subject

Publisher